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Conclusions: The QA process resulted in protocol compliant plans, 
generally improving based on the investigated criteria. The lack of 
differences in target coverage between sIMRT and rIMRT plans may 
partly be a result of the QA process ensuring comparability across the 
trial, however the more homogeneous dose distributions resulting 
from the rIMRT requires further investigation. 
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Purpose/Objective: To develop an analysis method for pretreatment 
verification based on the MLC leaf opening times (LOTs) measured 
with the imaging detector of the tomotherapy system. 
Materials and Methods: Twenty-five treatments from two 
tomotherapy units were delivered and acquired by the imaging 
detector of the system. Based on the fluence measured in the 
detector, LOTs of each treatment were extracted. 
LOTs at each gantry angle were summed taking into account the 
position of the beam at each projection calculated from treatment 
parameters such us field width and pitch, leading to a composite 
fluence map at each of the 51 gantry angles in which the tomotherapy 
system divides a rotation. These fluence maps have time units, and 
allow for analysis methods similar to those of field-by-field 
pretreatment verification. 
Mean differences in time between planned and delivered fluences, as 
well as standard deviation of that error distributions were obtained. 
Percentages of points within a 1%, 2%, 3% and 5% of the mean time of 
each treatment were also used in the analysis. 
These parameters were compared with conventional pretreatment 
verification methods on a cylindrical virtual water phantom. 
Results: Mean results of both machines are shown in the table, results 
show a good performance of both tomotherapy systems. Mean time 
errors lie within a 1% in all of the cases with standard deviations 
within a 3%. Those small differences in mean time errors suggest that 
important differences in dose are not caused by the MLC.  
Employing a 90 % of passing points as a threshold value for the 5% test 
would imply that only two of the treatments would have been 
rejected, while almost half of the treatments would have been 
rejected with the 3% criterion. Nevertheless, all of the treatments 
passed the verification based on ionization chamber and film. 
Therefore, the percentage of points within a 5% appears to be a good 
criterion for pretreatment verification, as it yields results similar to 
those obtained with our actual method based on the gamma index. 
No correlation was found between the results of the gamma index 
with those of fluence per angle. Gamma index results depend more on 
parameters such us treatment volume or shape of the dose 
distribution, while fluence results are more related with projection 
time and mean LOTs. 
 
 Mean values 
Tomotherapy 
1 
Tomotherapy 
2 
Cylindrical phantom 
verification 
Dose difference 
(%) -0,9 0,1 
% passing Gamma 
(3% 3mm) 99,3 98,1 
Imaging detector 
verification 
Time error (%) 0,4 0,2 
St. dev. of time 2,1 1,8 
error (%) 
% of points within 
1% 45,6 54,1 
% of points within 
2% 71,2 79,6 
% of points within 
3% 84,8 90,6 
% of points within 
5% 95,7 97,7 
 
Conclusions: A method for pretreatment verification based on fluence 
measurements with the on-board imaging detector was analyzed. The 
percentage of points within a 5% of the mean fluence time seems to 
be the more appropriate index for pretreatment verification. 
Nevertheless, treatments that passed the verification with 
conventional methods failed the proposed index. Therefore,further 
analysis on this matter should be developed.  
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Purpose/Objective: Complement existing EPID-based QA procedures 
for linear accelerators with specific VMAT tests covering the 
additional involved elements: dynamic MLC, dose modulation, gantry 
speed modulation and dose delivery during gantry rotation. 
Materials and Methods: Four different MLC types were used in this 
study: Varian Millennium™120MLC & HD120™MLC, and Elekta MLCi2 & 
Beam Modulator™. Tests criterions described in the commissioning 
procedure proposed by Ling et al. [Ling2008] were adapted 
- Test 1: leaf positions test using picket fence (PF) patter acquired at 
different gantry angles and during gantry rotation. 
- Test 2: variation of dose rate and gantry speed during gantry 
rotation. 
- Test 3: variation of dose rate and MLC leaf speed during gantry 
rotation. 
Some adaptations were done in order to take into account the 
differences in capabilities and geometry between the MLCs and 
accelerators, as well as to use EPID instead of films. On Varian Linacs, 
the EPID acquisition was done using fields of the DICOM RT Plans 
provided by the manufacturer. On Elekta Linacs it was done using the 
iComCAT software. The analysis of acquired EPID images was 
performed automatically using ARTISCAN (software solution developed 
by AQUILAB SAS, France). 
Results: All the key elements were correctly automatically detected 
in EPID images of all devices, regardless of the problems impacting 
image quality (Noise, Flexmap…). 
Test 1 was analyzed on 3 criterions for each slit of the PF: position of 
slit center, FWHM of the slit and dose delivered in the slit. In all the 
cases, every slit was correctly detected. The evaluation of the slit 
center position was sensitive enough to detect offset as small as 
0.5mm. The delivered dose was also a good indicator of leaf position 
errors. However, FWHM is not a good indicator as it did not correlate 
with induced width changes of the PF. 
Test 2 showed good homogeneity of the delivered dose regardless of 
the gantry speed or the dose rate on all devices. However, for close-
to-maximum gantry speed, slight dose rate fluctuations can occur. 
Test 3 showed a good homogeneity of the dose delivered on Varian 
devices. On the Elekta Beam Modulator, images showed lower 
delivered dose on the left and right borders of the test pattern. 
Repeated occurrences of test 2 and 3 over multiple days showed 
consistency of the results over time. 
Conclusions: Criterions tested in the Ling et al. commissioning 
procedure are as relevant for VMAT-capable Elekta linacs as they are 
for RapidArc-capable Varian linacs. The use of an automated solution 
to analyze EPID images ensures an objective, quantitative, as well as 
fast analysis for QA. However these criterions do not cover all the 
potential sources of error and additional tests will be evaluated. 
[Ling2008] Ling et al. 'Commissioning and quality assurance of 
RapidArc radiotherapy delivery system.' IJROBP 72.2 (2008): 575-581. 
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